Login to Your Account



CHMP Backs Biotie Therapies' Selincro in Alcohol Dependence

By Cormac Sheridan
Staff Writer

Saturday, December 15, 2012
europe_resized.jpg

Breaking out the champagne may not have been the appropriate reaction, but Biotie Therapies Oyj had reason to celebrate Friday, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for its alcohol dependence drug Selincro (nalmefene). Formal European Commission approval should follow in February, paving the way for a commercial launch shortly thereafter.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription